Record Status This is a bibliographic record of a published health technology assessment. No evaluation of the quality of this assessment has been made for the HTA database. Citation HAYES, Inc. Sofosbuvir-velpatasvir for chronic HCV infection. Lansdale: HAYES, Inc. Directory Publication. 2016 Authors' objectives Sofosbuvir-velpatasvir (Epclusa) is a "next-generation" once-daily direct-acting antiretroviral (DAA) combination oral regimen for the treatment of all 6 major hepatitis C virus (HCV) genotypes. The fixed-dose combination pill contains 400 mg of sofosbuvir and 100 mg of velpatasvir.
Rationale: Sofosbuvir-velpatasvir is intended to treat any genotype and subtype of HCV using an existing drug
with accepted efficacy, plus a new drug that is intended to improve efficacy by targeting HCV in a different way.
Relevant Questions: Does sofosbuvir-velpatasvir result in high rates of sustained virologic response (SVR) and low rates of treatment failure (i.e., virologic relapse)? How does sofosbuvir-velpatasvir compare with other treatments for HCV for increasing SVR rates, reducing treatment failure (i.e., virologic relapse) rates, or improving patient-oriented outcomes (e.g., quality of life)? What harms and complications are associated with sofosbuvir-velpatasvir? Have definitive patient selection criteria been established for sofosbuvir-velpatasvir for treatment of chronic HCV infection? Indexing Status Subject indexing assigned by CRD MeSH Carbamates; Hepatitis C, Chronic; Heterocyclic Compounds with 4 or More Rings; Humans; Sofosbuvir Language Published English Country of organisation United States English summary An English language summary is available. Address for correspondence HAYES, Inc., 157 S. Broad Street, Suite 200, Lansdale, PA 19446, USA. Tel: 215 855 0615; Fax: 215 855 5218 Email: hayesinfo@hayesinc.com AccessionNumber 32017000066 Date abstract record published 05/01/2017 |